WO2001070764A2 - Epitopes - Google Patents
Epitopes Download PDFInfo
- Publication number
- WO2001070764A2 WO2001070764A2 PCT/GB2001/001205 GB0101205W WO0170764A2 WO 2001070764 A2 WO2001070764 A2 WO 2001070764A2 GB 0101205 W GB0101205 W GB 0101205W WO 0170764 A2 WO0170764 A2 WO 0170764A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- polypeptide
- sequence
- peptide
- Prior art date
Links
- 241000187479 Mycobacterium tuberculosis Species 0.000 title abstract description 3
- 239000000427 antigen Substances 0.000 title description 14
- 108091007433 antigens Proteins 0.000 title description 14
- 102000036639 antigens Human genes 0.000 title description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 113
- 229910052721 tungsten Inorganic materials 0.000 claims abstract description 15
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 11
- 229910052727 yttrium Inorganic materials 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 256
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 137
- 210000004027 cell Anatomy 0.000 claims description 109
- 229920001184 polypeptide Polymers 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 52
- 230000027455 binding Effects 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 238000002255 vaccination Methods 0.000 claims description 29
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 28
- 239000013604 expression vector Substances 0.000 claims description 28
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 27
- 108091008874 T cell receptors Proteins 0.000 claims description 27
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 27
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 26
- 230000005867 T cell response Effects 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 25
- 108010087967 type I signal peptidase Proteins 0.000 claims description 20
- 201000008827 tuberculosis Diseases 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 16
- 241000186359 Mycobacterium Species 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 11
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 7
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 101150038222 mpt53 gene Proteins 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 101710132601 Capsid protein Proteins 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 101710181935 Phosphate-binding protein PstS 1 Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 description 38
- 102000006390 HLA-B Antigens Human genes 0.000 description 31
- 239000003795 chemical substances by application Substances 0.000 description 30
- 108010058607 HLA-B Antigens Proteins 0.000 description 29
- 239000002245 particle Substances 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 22
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000000523 sample Substances 0.000 description 12
- 238000004422 calculation algorithm Methods 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- -1 IFNγ Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108090001030 Lipoproteins Proteins 0.000 description 7
- 102000004895 Lipoproteins Human genes 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 6
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 5
- 239000010937 tungsten Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 4
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 101710178472 Tegument protein Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000006433 tumor necrosis factor production Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 2
- 108010008553 HLA-B*07 antigen Proteins 0.000 description 2
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 2
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 101900222562 Influenza A virus Nucleoprotein Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 101100181595 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) lepB gene Proteins 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000047279 human B2M Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000465865 Geodermatophilaceae bacterium Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 101001043272 Mycobacterium tuberculosis (strain ATCC 25177 / H37Ra) Lipoprotein LpqH Proteins 0.000 description 1
- 101100024115 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) mpt53 gene Proteins 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710148061 Probable signal peptidase I Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 101150086609 groEL2 gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000052622 human IL7 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
- A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention relates to prophylactic or therapeutic vaccination against mycobacterial infection and to polynucleotides and polypeptides which can be used for such vaccination.
- Mycobacterium tuberculosis the causative agent of human tuberculosis, is re- emerging as a major public health risk world- wide.
- the World Health Organisation has estimated that about one third of the world's population is infected with
- HLA-B*35 restricted CD8 T cell epitopes in M.tuberculosis proteins We identified a number of peptides that carried the HLF-B*3501 peptide-binding motif. In vitro binding assays revealed five peptides that bound very strongly to HLA-B*3501, and bound to HLA-B*5301 too. One of the peptides caused CD8 T cells to kill M. tuberculosis-infected macrophages and induced intracellular IFN ⁇ and TNF ⁇ production in activated (i.e. CD69*) CD8 cells. This peptide is composed of amino acids 201 to 209 of Signal peptidase-I (EPYLDPATM; Spase-I 20 ⁇ -209 ).
- EPYLDPATM Signal peptidase-I
- - Xi is E, X 2 is Y, X is L, X is D, X 5 is P, X 6 is A, X is T, X 8 is V, L, I or M and X 9 is absent;
- - Xi is L, X is G, X 3 is T, X 4 is A, X 5 and X 6 are each V, X 7 is P, X 8 is V, L, I or M and X 9 is absent,
- - Xi is T, X 2 is A, X 3 is N, X 4 is Q, X 5 is A, X 6 is I, X 7 is S, X 8 is V, L, I or M and X 9 is absent; or
- X 2 is W
- X 3 is Q
- X 4 is P
- X 5 is A
- X 6 is F
- X 8 is F, Y or W and X is absent or F, Y or W; or an epitope sequence which is an analogue of (I) and which can be recognised by a
- CD8 T cell that recognises (I);
- an expression vector comprising a polynucleotide encoding a said polypeptide (a) operably linked to a regulatory sequence capable of providing for expression of the said polypeptide (a); for use in the manufacture of a medicament for vaccinating prophylactically or therapeutically against infection by a mycobacterium.
- polypeptide (a) and expression vector (b) are capable of stimulating a
- the invention further provides a vaccine composition which comprises a polypeptide or expression vector as defined above and an adjuvant or delivery system capable of stimulating a CD8 T cell response.
- a method of vaccinating a pre-selected host against a mycobacterial infection comprising administering to the host an effective amount of a polypeptide, expression vector or vaccine composition as defined above; specific novel polypeptides, expression vectors and cells, suitable for use in vaccinating against infection by a mycobacterium; a product which selectively binds a T cell receptor that recognises an epitope sequence as defined above such as the epitope sequence of formula (I), which product comprises an HLA molecule, or a fragment thereof, comprising a peptide with the sequence of the epitope sequence in its peptide binding groove; a method of detecting in a population of T cells the presence or absence of CD8 T cells that recognise an epitope sequence as defined above such as the epitope sequence of formula (I), said method comprising:
- FIG. 1 Screening of Spase-I complex-derived peptides for binding to HLA-B*3501.
- RMA-S B*3501 cells were pulsed with 50 ⁇ M unlabeled competitor peptide and 1 ⁇ M of FL-labeled reference peptide as described in the Materials & Methods section of Example 1.
- Results are expressed as % inhibition of the maximum signal of the FL-labeled reference peptide.
- the vertical dotted line identifies peptides that inhibited the maximum signal by >75%.
- FIG. 1 Titration of HLA-B*3501 binding peptides.
- RMA-S B*3501 cells were pulsed with a fixed concentration of 1 ⁇ M of FL-labeled reference peptide to yield a maximum signal.
- Increasing amounts of unlabeled competitor peptides were added to reduce the signal (Van der Burg et al, Hum. Immunol. 44, 189-198, 1995).
- Results are expressed as % inhibition of the maximum signal of the FL-labeled reference peptide.
- the concentration at which the maximum signal was inhibited by 50% corresponds to the 1C 50 -value.
- Figure 4 Killing of peptide pulsed- and M. tuberculosis-infected autologous macrophages. Short-term cultures of PBMC stimulated with peptide SPase-I 201-209 were tested in standard 51 Chromium-release assays. CTL activity is expressed as % specific lysis (mean+SD). Effector cells were tested at E/T ratio of 50:1 on control targets (white bars), and at E/T ratio of 5:1 (dotted bars) and 50:1 (black bars) on peptide-pulsed macrophages, and at E/T ratio of 50:1 on M. tuberculosis-infected macrophages (hatched bars). Figure 5.
- HLA-B*3501 restricted IFN ⁇ production by CD8 + CD69 + T cells in response to mycobacteria-derived peptides Short-term cultures of PBMC stimulated with peptide SPase-l 201- 09 were co-cuftivated for 6 h with RMA-S B*3501 cells pulsed with a control peptide, HIV- 1 SF 2 Nef7 -80 (4T6R) (panel a) or the specific peptide (panel b). Cytokine secretion was blocked by Brefeldin A. Surface markers CD8 and CD69 and intracellular IFN ⁇ and TNF ⁇ were stained following fixation and permeabilization of cells. Dot plots show log fluorescence intensity.
- CD8 + bright T cells were gated in the fiuorescence-3 versus side scatter light plots.
- Quadrant markers for CD69, IFN ⁇ and TNF ⁇ were set using the proper isotype control reagents. Frequencies of positive cells are given as % of the gated CD8 + T cells.
- SEQ ID NO: 1 shows the amino acid sequence of SPase-I o ⁇ -2 o 9
- SEQ ID NO: 2 shows the amino acid sequence of 38kDa-LP ⁇ 75-183
- SEQ ID NO: 3 shows the amino acid sequence of 38kDa-LP 2 2-3 oo
- SEQ ID NO: 4 shows the amino acid sequence of MPT53 134- ⁇ 43
- SEQ ID NO: 5 shows the amino acid sequence of MPT53 134- ⁇ 2
- SEQ ID NO: 6 shows the DNA and amino acid sequences of SPase-I
- SEQ ID NO: 7 shows the amino acid sequence of SPase-I
- SEQ ID NO: 8 shows the DNA and amino acid sequences of 38kDa-LP
- SEQ ID NO: 9 shows the amino acid sequence of 38kDa-LP
- SEQ ID NO: 10 shows the DNA and amino acid sequences of MPT 3
- SEQ ID NO: 11 shows the amino acid sequence of MPT53.
- polypeptides which consist essentially of an epitope sequence of formula (I):
- - is E
- X 2 is Y
- X 3 is L
- X4 is D
- X 5 is P
- X 6 is A
- X 7 is T
- X 8 is a hydrophobic amino acid, typically V, L, I or M and X 9 is absent;
- - X is L, X 2 is G, X 3 is T, X 4 is A, X 5 and X 6 are each V, X 7 is P, X 8 is a hydrophobic amino acid, typically V, L, I or M and " X 9 is absent;
- - Xi is T, X 2 is A, X 3 is N, X 4 is Q, X 5 is A, X 6 is I, X 7 is S, X 8 is a hydrophobic amino acid, typically V, L, T or M, and X 9 is absent; or
- and X 7 are each V, X 2 is W, X 3 is Q, » is P, X 5 is A, X 6 is F, X 8 is an aromatic amino acid, typically F, Y or W, and X 9 is absent or an aromatic amino acid, typically F, Y or W.
- the polypeptides can consist essentially of an epitope sequence which is an analogue of (I) and which can be recognised by a CD8 T cell that recognises (I).
- the invention is also concerned with expression vectors which comprise a polynucleotide encoding such polypeptides and in which the polynucleotide is operably linked to a regulatory sequence capable of providing for expression of the polypeptide.
- the polypeptides and expression vectors are useful for vaccinating a host against infection by a mycobacterium. Such a vaccination may be prophylactic (of a host which does not have a mycobacterial infection) or therapeutic (of a host that does have a mycobacterial infection).
- the host which is vaccinated is generally a mammal, such as a human or animal, typically one which can be naturally or artificially infected by a mycobacterium.
- the host may be a primate, cow or badger.
- the host may be at risk of a mycobacterial infection, typically because it is resident in a location in which mycobacterial infection is endemic.
- the host may be susceptible to mycobacterial infection due to malnutrition or infection by other pathogens, such as HIV.
- the mycobacterium against which the host is vaccinated expresses the protein from which the epitope is derived, i.e. SPase-I, 38kDa LP or MPT 53.
- the mycobacterium against which the host is vaccinated expresses another protein which contains the epitope sequence.
- the protein may therefore be a homologue of the amino acid sequence of SPase-I, 38 kDa LP or MPT 53 shown as SEQ ID NOS: 6 to 11.
- the mycobacterium is typically pathogenic and capable of infecting mammals, such as those mammals discussed above.
- the mycobacterium is typically M.tuberculosis, M.marinum, M.kansasii, M. bovis or M.avium.
- the vaccination stimulates a CD 8 T cell response to the epitope (which may comprise responses to different epitopes of the invention as defined by (I) or the analogue of (I)).
- the vaccination may or may not lead to a CD8 T cell response to one or more other epitopes in SPase-1, ⁇ 38 kDa LP or MPT 53, or to one or more epitopes in other mycobacterial proteins.
- the vaccination may or may not lead to an antibody response that recognises an epitope in SPase-I, 38 kDa LP or MPT 53 or in 1, 2, 3 or more other mycobacterial proteins.
- the epitope sequence may have the sequence of formula (I).
- the epitope has the sequence EPYLDPATM (SEQ ID NO: 1, SPase-I 20 ⁇ -209 ),
- the epitope may have a sequence which is an analogue of (I) which is recognised by a T cell that recognises (I).
- T cell recognition includes the binding of the T cell receptor to the analogue, and typically also antigen-specific functional activation of the T cell.
- An analogue of (I) is typically an analogue of any of SEQ ID NOS: 1 to 5.
- a peptide with the sequence of the analogue is capable of inhibiting the binding of a peptide of sequence (I) (referred to as peptide (I) herein) to a T cell receptor.
- a peptide of sequence (I) referred to as peptide (I) herein
- the binding of the analogue peptide to the T cell receptor is a specific binding.
- an MHC class I molecule such as HLA-B*3501.
- T cell receptor used binds specifically to the peptide (I).
- T cells with such receptors can be produced by stimulating antigen naive T cells in vitro or in vivo with peptide (I), which is generally presented to the T cell by an appropriate HLA molecule.
- Antigen-specific functional activation of the T cell by the analogue peptide may be measured using suitable technique discussed herein.
- the analogue peptide causes such activation when it is presented to the T cell associated with an MHC class I molecule, such as HLA-B*3501 (for example on the surface of a cell).
- the analogue peptide (or analogue sequence within a larger peptide) is typically capable of stimulating a CD8 ⁇ T cell response directed to peptide (I), for example when administered to a human or animal (such as in any of the forms or with any of the adjuvants mentioned herein).
- a response may be protective against tuberculosis in an animal model or of therapeutic benefit in a human patient.
- the analogue peptide typically has a shape, size, flexibility or electronic configuration which is substantially similar to peptide (I). It is typically a derivative of the peptide (I).
- the analogue peptide may also be able to bind other specific binding agents that bind the peptide (I).
- an agent may be HLA-B*3501.
- the analogue peptide typically binds to antibodies specific for peptide (I), and thus inhibits binding of peptide (I) to such an antibody.
- the analogue peptide is either a peptide or non-peptide or may comprise both peptide and non-peptide portions. Such a peptide or peptide portion may have homology with the peptide (I) (e.g. homology with any of SEQ ID NOS: 1 to 5).
- the analogue sequence may comprise 1, 2, 3, 4 or more non-natural amino acids, for example amino acids with a side chain different from natural amino acids.
- the non-natural amino acid will have an N terminus and/or a C terminus.
- the non-natural amino acid may be an L- or a D-amino acid.
- the analogue sequence is a peptide sequence which comprises one or more modifications.
- the modification may be any of those mentioned herein which can be present on the polypeptide of the invention.
- the modification can be present on any of the amino acids of the analogue sequence, such as any of the amino acids responsible for binding the MHC molecule or which contact the T cell receptor during recognition by a T cell.
- the analogue sequence is typically designed or selected by computational means and then synthesised using methods known in the art. Alternatively the analogue can be selected from a library of compounds.
- the library from which the analogue sequence is selected is typically a library comprising peptides, such as peptides which have an HLA-B*3501 binding motif.
- the library may be a combinatorial library or a microorganism display library, such as a phage display library.
- the library of compounds may be expressed in the display library in the form of being bound to a MHC class I molecule, such as HLA-B*3501.
- An analogue peptide or sequence can be selected from the library based on any of the characteristics mentioned above, such as the ability to mimic the binding characteristics of peptide (I), for example the ability to bind a T cell receptor, HLA- B*3501 or antibody which recognises peptide (I).
- the analogue may be selected based on the ability to cause antigen specific functional activity of a T cell that recognises peptide (I) (for example using any of the suitable techniques mentioned herein).
- the polypeptide is generally 8 to 2000 amino acids in length, such as 9 to 1000, 10 to 500, 11 to 200, 12 to 100 or 15 to 50 amino acids in length. Typically the polypeptide has a length of up to 50 amino acids.
- the polypeptide is typically a non-naturally occurring protein, such as a fusion protein comprising sequence from the same or different proteins.
- a preferred fusion protein comprises a derivative of the sequence of SPase-I, 38kDa-LP or MPT 53 discussed below.
- the polypeptide may comprise a sequence which is a derivative of the sequence of SPase-I, 38kDa-LP or MPT 53 (e.g. of the sequence shown in SEQ ID NOS: 6 and 7, SEQ ID NOS: 8 and 9 or SEQ ID NOS: 10 and 11).
- sequence is typically not a derivative of the sequence of SPase-I, 38kDa-LP or MPT53 (derivative being defined according to any manner mentioned herein).
- the derivative sequence will typically comprise the epitope sequence.
- Such a derivative may be fragment of SPase-I, 38kDa-LP or MPT53.
- the fragment only contains SPase-I, 38kDa-LP or MPT53 sequence that lies close to the epitope sequence. In one embodiment the fragment only comprises the epitope sequence.
- the derivative of the SPase-I, 38kDa-LP or MPT53 sequence may be homologous to the whole SPase-I, 38KDa-LP or MPT53 sequence or any of the fragments thereof mentioned above.
- the polypeptide typically comprises 1, 2, 3, 4, or from 5 to 10, or more copies of the epitope sequence, which may be the same or different.
- a linker sequence may or may not separate the epitope sequences and or there may or may not be additional (non-epitope) sequence at the N terminal or C terminal of the peptide.
- the peptide comprises 1, 2, 3 or more linkers.
- the linkers are typically 1, 2, 3, 4 or more amino acids in length.
- 1, 2 or more, or all of the epitope sequences may be contiguous with each other or separated from each other.
- the polypeptide may also comprise sequence which enhances the immunogenicity of the epitope sequence. Such sequences are discussed below.
- the polypeptide may also comprise 1, 2, 3, 4 or from 5 to 10, or more, other epitope sequences, such as other CD8 T cell epitope sequences (which are recognised by different T cells), CD4 T cell epitopes or antibody epitopes.
- other epitope sequences such as other CD8 T cell epitope sequences (which are recognised by different T cells), CD4 T cell epitopes or antibody epitopes.
- the other epitope(s) may be mycobacterial epitopes (such as epitopes from mycobacterial proteins other than the protein from which the epitope sequence is derived).
- the other epitope(s) may be of another pathogen, such as a viral pathogen (e.g. HIV).
- the other epitope(s) may be of Clostridium (e.g. from the Clostridium tetani neurotoxin fragment C), hepatitis B (e.g. from core or surface protein).
- the other epitope(s) may be artificial or consensus epitope (such as PADRE), for example as described in del Guercio et al (1997) Proc. Natl. Acad. Sci. USA 93, 11786-91.
- the polypeptide is modified, for example by a natural post-translational modification (e.g. glycosylation) or an artificial modification.
- the peptide may comprise the modifications that occur when it is expressed in a eukaryotic (e.g. human) or prokaryotic (e.g. E. coli) cell.
- the peptide lacks glycosylation.
- the modification may provide a chemical moiety (typically by substitution of a hydrogen, e.g. the hydrogen of a C-H bond), such as an amino, acetyl, hydroxy or halogen (e.g. fluorine) group or carbohydrate group.
- the modification is present on the N or C terminus.
- the polypeptide is typically capable of being processed by the class I antigen presenting pathway of a cell to provide a peptide (peptide (I) or the analogue peptide) on the surface of the cell bound a MHC class I molecule. Typically such a cell is able to present the peptide to a T cell.
- the polypeptide may be produced synthetically or expressed in a recombinant system.
- Solid phase or solution phase synthesis methods may be used.
- solid phase synthesis the amino acid sequence of the desired peptide is built up sequentially from the C terminal amino acid which is bound to an insoluble resin. When the desired peptide has been produced it is cleaved from the resin.
- solution phase synthesis the desired peptide is again built up from the C terminal amino acid. The carboxy group of this amino acid remains blocked throughout by a suitable protecting group, which is removed at the end of the synthesis.
- each amino acid added to the reaction system typically has a protected amino group and an activated carboxy group. Functional side chains are also protected.
- the expression vector capable of expressing the polypeptide is a polynucleotide, typically DNA or RNA, and is typically single or double stranded.
- the polynucleotide may be linear or circular (e.g. a plasmid).
- RNA it is capable of being directly translated to provide the polypeptide (and typically does not contain the sequences mentioned below which aid transcription).
- the vector comprises a sequence which encodes the polypeptide, which is typically operably linked to a control sequence capable of providing for expression of the coding sequence.
- the vector comprises 5' and 3' to the coding sequence sequences which aid expression, such as aiding transcription and/or translation of the coding sequence.
- the vector comprises a promoter, enhancer, transcription terminator, polyadenylation signal, polyA tail, intron, translation initiation codon or translation stop codon.
- the expression vector is capable of expressing the polypeptide.
- the vector is capable of expressing the polypeptide in a cell of the host (using the host cell transcription and translation mechanisms).
- the expression vector is within a cellular vector (as discussed below), and therefore is capable of expressing the polypeptide in the cellular vector (using the transcription and translation mechanisms of the cellular vector).
- the vector may also be capable of expressing a substance which enhances the immunogenicity of the polypeptide (such as any such substance mentioned herein).
- the vector comprises 2 or more coding sequences, and may be capable of expressing 2 or more different polypeptides of the invention.
- the vector may be associated with (e.g. within) a moiety which aids delivery or expression of the vector. Preferably such a moiety aids delivery of the polypeptide expressed by the vector to the class I processing and presentation pathway.
- a moiety may be a virus or cell.
- the vector is present in a virus vector (i.e. a viral vector), such as a virus which is capable of stimulating a CD8 T cell response (e.g. a vaccinia virus).
- the virus is typically one whose wild-type is capable of infecting the host.
- the cell in which the vector may be present may be a prokaryotic (e.g. bacterium) or eukaryotic cell. It is typically the cell of a pathogen which is capable of infecting the host. Such a pathogen may be virulent in its wild-type form.
- the cell is of a mycobacterium (such as any of those mentioned herein including M.bovis bacillus Calmette-Guerin).
- the cell may be of the species of the host or may be a cell which has previously been extracted from the host (and optionally cultured and/or replicated in vitro). Such a cell may be any type of cell mentioned herein, and is typically a professional antigen presenting cell.
- a recombinant replicable polynucleotide vector which comprises a sequence that encodes the polypeptide of the invention may also be mentioned. In one embodiment this is the same as the expression vector of the invention.
- the vector may be replicated in a compatible cell.
- the invention provides a method of making vectors of the invention by introducing a polynucleotide sequence that encodes the polypeptide of the invention into a replicable vector, introducing the vector into a compatible cell, and growing the cell under conditions which bring about replication of the vector.
- the vector may be recovered from the cell. Suitable cells are described below.
- the sequence which encodes the polypeptide is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the cell.
- operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
- a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
- Such vectors may be transformed into a suitable cell to provide for expression of a polypeptide of the invention.
- a polypeptide according to the invention can be obtained by cultivating a cell transformed or transfected with a vector as described above under conditions to provide for expression of the polypeptide, and recovering the expressed polypeptide.
- the vector may be for example, plasmid, virus or phage vector provided with an origin of replication, optionally a promoter for the expression of the coding sequence and optionally a regulator of the promoter.
- the vector may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid. Promoters and other expression regulation signals may be selected to be compatible with the cell for which the vector is designed.
- Cells transformed (or transfected) with the vector will be chosen to be compatible with the said vector and preferably will be bacterial such as E. coli. Alternatively they may be cells of a human or animal cell line such as CHO or COS cells, or yeast or insect cells. The cells may also be cells of a non-human animal such as a sheep or rabbit or plant cells.
- polypeptide may comprise a sequence which enhances the immunogenicity of the epitope.
- the polypeptide or expression vector may also be associated with a substance (which may be a peptide or non-peptide substance) or may be in a form which is capable of enhancing the immunogenicity of the epitope. Generally this will enhance the speed and/or magnitude of the CD8 T cell response to the epitope, and thus generally after vaccination a larger number of CD8 T cells specific for the epitope will be present in the host (for example in the peripheral blood).
- the substance may act as adjuvant or may target the peptide to antigen presenting cells (APCs) or to compartments in the antigen processing pathway, for example acting as a carrier protein.
- the sequence may stimulate a T helper response, such as a response that favours a CD8 T cell response, and thus may comprise a T helper (e.g. Thl) cell epitope.
- Preferred substances which enhance immunogenicity include sequence from the hepatitis B core antigen, sequence from a stress protein or sequence from Clostridium tetani neurotoxin fragment C.
- the stress protein is typically a bacterial (e.g. mycobacterial) heat shock protein (HSP) or a protein which has homology with such a protein, such as mycobacterial or E. coli proteins of the HSP 60 and HSP 70 families (e.g. HSP 65 or HSP 71 of mycobacteria) or mammalian homologue (e.g. gp96 of mice or humans, Anthony et al (1999) Vaccine 17, 373-83).
- HSP heat shock protein
- mammalian homologue e.g. gp96 of mice or humans, Anthony et al (1999) Vaccine 17, 373-83.
- the substance may cause the polypeptide or vector to adopt a particulate form.
- the substance may be a virus or virus-like particle (such as a yeast Ty particle, e.g. as in Allsopp et al (1996) Eur. J. Immunol. 26, 1951-9).
- the substance may be a cytokine, such as a cytokine which stimulates a MHC class I restricted T cell response or favourable MHC class II restricted T cell response (e.g. IL-2, IL-7, IL-12, IFN- ⁇ or GMCSF).
- the substance may be, for example, CFA, a muramyl dipeptide (e.g.
- lipid A monophosphoryl lipid A
- lipopolysaccharide e.g. from B. abortus
- liposomes SAF-1
- a saponin e.g. Quil A
- keyhole limpet hemocyanin beta 2-microglobulin
- mannan e.g. oxidised mannan
- acrylic based microbead e.g. oil in water or water in oil
- soybean emulsion e.g as in Hioe et al (1996) Vaccine 14, 412-8).
- a cell may incorporate the polypeptide or vector.
- the polypeptide In the case of the polypeptide, it is typically presented on the surface of the cell.
- Such a cell is generally an antigen presenting cell such as a dendritic cell.
- the cell can thus be loaded with the polypeptide.
- dendritic cells that may be achieved as described in Ah et al, Transplantation 69, 221-226, 2000.
- the polypeptide or vector may be administered to a host in the form of such a cell.
- the cell has previously been obtained from the same individual, i.e. is an autologous cell.
- the particular route of administration used may aid the stimulating of a CD8 T cell response, and thus the polypeptide vector may be provided in a form suitable for administering by such a route. Delivery by an intramuscular route or by biolistic means is preferred.
- a low dose of antigen favours the development of a CD8 T cell response.
- a suitable low dose of the polypeptide or vector may be administered.
- the polypeptide or vector may thus be in an amount and concentration that is suitable for administering to provide an appropriate low dose.
- the vector is administered: in the form of "naked DNA”.
- the product of the invention selectively binds a T cell receptor of the T cell of the invention, typically in a reversible manner. Such a product is generally able to inhibit the binding of epitope peptide (e.g. bound to an MHC molecule) to the T cell receptor.
- the product comprises an HLA molecule, or a fragment thereof, comprising a peptide with the sequence of the epitope sequence in its peptide binding groove.
- the HLA molecule is generally a MHC class I molecule (e.g. HLA- B*3501).
- Such molecules comprise an ⁇ chain and a ⁇ chain.
- the fragment may comprise only the extracellular domain of the HLA molecule.
- the fragment may or may not be capable of binding a cell membrane.
- the HLA molecule an ⁇ chain and a ⁇ chain which are not naturally occurring chains, but will typically have homology with naturally occurring chains (such as those of HLA- B*3501).
- 2, 3, 4 or more products are linked together in a multimer.
- the products in the multimer may be linked by a covalent bond or by non-covalent means.
- the products are linked by a streptavidin-biotin interaction, and thus typically the products comprise a biotin portion (typically chemically linked to or in a fusion protein with the product) which allows the products to be linked together by streptavidin.
- the multimer generally has a higher binding affinity to the T cell receptor of the invention than the product.
- the multimer may also comprise a detectable label, such as a radioactive or a light detectable (e.g. fluorescent) label. The label may allow the multimer to be sorted by flow cytometry (e.g.
- the multimer when the multimer is bound to a T cell receptor which is present on a T cell of the invention).
- the multimer may be a soluble multimer or may be capable of associating with a cell membrane.
- the multimer is attached to a solid support, such as a microtitre plate.
- the invention provides a method of detecting the presence or absence of CD8 T cells that recognise the epitope sequence (which may be in the form of the product discussed above).
- the determination of whether the T cells recognise the epitope sequence is done by detecting a change in the state of the T cells in the presence of the epitope sequence or determining whether the T cells bind the epitope sequence.
- the change in state is generally caused by antigen specific functional activity of the T cell after the T cell receptor binds the epitope sequence.
- the epitope sequence is bound to an MHC class I molecule, which is typically present on the surface of an APC (antigen presenting cell) and typically presented by an appropriate HLA molecule.
- the change in state of the T cell may be the start of or increase in the expression of a substance in the T cells and/or secretion of a substance from the T cell, such as a cytokine (e.g. IFN- ⁇ , IL-2 or TNF- ⁇ ). Determination of IFN- ⁇ expression or secretion is particularly preferred.
- the substance can typically be detected by allowing it to bind to a specific binding agent and then measuring the presence of the specific binding agent/substance complex.
- the specific binding agent is typically an antibody, such as polyclonal or monoclonal antibodies. Antibodies to cytokines are commercially available, or can be made using standard techniques.
- the specific binding agent is immobilised on a solid support (and thus the method may based on the ELISPOT assay to detect secretion of the substance).
- the solid support can optionally be washed to remove material which is not specifically bound to the agent.
- the agent/substance complex may be detected by using a second binding agent which will bind the complex.
- the second agent binds the substance at a site which is different from the site which binds the first agent.
- the second agent is preferably an antibody and is labelled directly or indirectly by a detectable label.
- the second agent may be detected by a third agent which is typically labelled directly or indirectly by a detectable label.
- the second agent may comprise a biotin moiety, allowing detection by a third agent which comprises a streptavidin moiety and typically alkaline phosphatase as a detectable label.
- the change in state of the T cell which can be measured may be the increase in the uptake of substances by the T cell, such as the uptake of thymidine.
- the change in state may be an increase in the size of the T cells, or proliferation of the T cells, or a change in cell surface markers on the T cell.
- the change in state may be the killing (by the T cell) of a cell which presents the epitope sequence.
- the determination of whether the T cells recognise the peptide may be carried out using a CTL assay.
- the T cells which are contacted in the method are taken from the host in a blood sample, although other types of samples which contain T cells can be used.
- the sample may be added directly to the assay or may be processed first.
- the processing may comprise diluting of the sample, for example with culture medium or buffer.
- the sample is diluted from 1.5 to 100 fold, for example 2 to 50 or 5 to 10 fold.
- the processing may comprise separation of components of the sample.
- MCs mononuclear cells
- the MCs will include the T cells and APCs.
- the APCs present in the separated MCs can present the peptide to the T cells.
- T cells in one embodiment only CD8 T cells
- PBMCs peripheral blood mononuclear cells
- MCs and T cells can be separated from the sample using techniques known in the art.
- the T cells used in the assay can be in the form of unprocessed or diluted samples, or are freshly isolated T cells (such as in the form of freshly isolated MCs or PBMCs) which are used directly ex vivo, i.e. they are not cultured before being used in the method. However, more typically the T cells are cultured before use, for example in the presence of the epitope sequence, and generally also exogenous growth promoting cytokines. During culturing the epitope sequence is typically present on the surface of APCs, such as the APC used in the method. Pre-culturing of the T cells may lead to an increase in the sensitivity of the method.
- the APC which is typically used in the method is from the same host as the T cell or from a different host.
- the APC can be an non-professional APC, but is typically a professional APC, such as any of the APCs mentioned herein.
- the APC maybe an artificial APC.
- the APC is a cell which is capable of presenting the peptide to a T cell. It is typically separated from the same sample as the T cell and is typically co-purified with the T cell. Thus the APC may be present in MCs or
- the APC is typically a freshly isolated ex vivo cell or a cultured cell. It may be in the form of a cell line, such as a short term or immortalised cell line. The APC may express empty MHC class I molecules on its surface.
- polypeptide per se is added directly to an assay comprising T cells and APCs. This may be taken up directly onto the surface of the APCs (particularly if the APCs express empty MHC class I molecules on their surface).
- polypeptide is provided to the APC in the absence of the T cell. The APC is then provided to the T cell, typically after being allowed to present the epitope sequence on its surface.
- the duration for which the epitope sequence is contacted with the T cells will vary depending on the method used for determining recognition of the peptide.
- concentration of T cells used is 10 3 /ml to 10 9 /ml, preferably 10 5 /ml to 10 7 /ml.
- concentration is typically from 0.1 to 1000 ⁇ g/ml, preferably 10 to lOO ⁇ g/ml.
- length of time for which the T cells are incubated in the assay is from 4 to 24 hours, preferably 6 to 16 hours, and in one embodiment for at least 40, 120 or 180 hours.
- the determination of the recognition of the epitope sequence by the T cells may be done by measuring the binding of the epitope sequence to the T cells.
- T cells which bind the peptide can be counted and sorted based on this binding, for example using a FACS machine.
- the presence of T cells which recognise the peptide will be deemed to occur if the frequency of cells identified using the peptide is above a 'control' value (i.e. above the frequency of antigen naive T cells which recognise the epitope sequence).
- the frequency of antigen- experienced T cells specific for a particular epitope during a disease state would be expected to be between 5 and 60% of the total CD8 T cells.
- the invention provides a method of diagnosis of a mycobacterial infection or of testing the effectiveness of a vaccination against a mycobacterial infection. It may not be possible to distinguish between the host having a CD8 T cell response to the epitope due to mycobacterial infection or due to vaccination. A host which is found not to have a CD8 T cell response (or a level of CD8 T cell response which is not sufficient to provide protective/sterilising immunity) to the epitope may be selected for vaccination to stimulate such a T cell response (e.g. by the vaccination method mentioned herein). In the method of diagnosis or testing the effectiveness of a vaccination of the invention the presence or absence of the CD8 T cell response is typically determined by the method of identifying a CD8 T cell response discussed above.
- the invention also provides a CD8 T cell that recognises the epitope sequence, i.e. the TCR of the T cell is able to bind a peptide with the epitope sequence (typically when the peptide is bound to an appropriate HLA molecule and presented on a cell).
- the T cell is able to undergo antigen specific functional activation upon binding the epitope sequence.
- the T cell typically produces IFN- ⁇ , and typically does not produce IL-4, IL-10 or TGF- ⁇ .
- the T cell r may be cyto toxic and typically contains cytotoxic granules comprising perform, granzymes and granulysin.
- the T cell is cytotoxic towards autologous macrophages infected with a mycobacterium (such as any mycobacterium mentioned herein).
- the T cell is not immunosuppressive.
- the T cell has previously been extracted from the same host and has been replicated in vitro.
- Such replication may comprise culturing in the presence of the epitope sequence (typically presented on the surface of a cell).
- the cell may be used in a method of treating a mycobacterial infection.
- the invention provides a T cell receptor (TCR), or fragment thereof, which is capable of binding the epitope sequence.
- TCR may have any of the properties of the TCR present on the T cell of the invention.
- the epitope sequence is generally bound to an MHC molecule during binding with the TCR.
- the polypeptide, expression vector, cell (including T cell), product and TCR (or fragment thereof) of the invention may be in substantially purified form. They may be in substantially isolated form, in which case they will generally comprise at least 80% e.g. at least 90, 95, 97 or 99% of the polypeptide, polynucleotide, cells or dry mass in the preparation.
- the polypeptide, expression vector, product or TCR (or fragment thereof) is typically substantially free of other cellular components, or free of other mycobacterial components, or free of (other) polypeptide or polynucleotide.
- the polypeptide, expression vector, cell or product may be used in any of the above forms in any aspect of the invention mentioned herein.
- the polypeptide and expression vector discussed above in any form or in association with any other agent is included in the termed "vaccination agent" below.
- An effective non-toxic amount of such a vaccination agent may be given to a preselected host, such as a human or non-human.
- the vaccination agent may be administered prophylactically to a host who does not have a mycobacterial infection in order to prevent the individual developing a mycobacterial infection.
- the vaccination agent may be administered therapeutically to a host who has a mycobacterial infection, in order to treat the infection (including ameliorating the symptoms of the disease).
- the T cells of the invention may be administered in an effective non-toxic amount to a patient in need thereof, such as a patient with a mycobacterial infection.
- the invention provides the vaccination agent and the T cells for use in a method of treating the human or animal body by therapy, and for use in the manufacture of a medicament for the treatment of a mycobacterial infection.
- the vaccination agent or the T cells may be given to the host in one or more administrations. Typically after the initial administration a 'booster' can be given. Typically the host is given 1, 2, 3 or more separate administrations, each of which is separated by at least 12 hours, 1 day, 2, days, 7 days, 14 days, 1 month or more.
- the vaccination agent or T cells may be in the form of a pharmaceutical composition which comprises the vaccination agent or T cells and a pharmaceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline.
- the administration is (and thus the composition is formulated for) parenteral, intravenous, intramuscular, subcutaneous, transdermal, intradermal, oral, intranasal, intravaginal, or intrarectal administration.
- a preferred method of delivering the vaccination agent is by biolistic means (a particle-mediated method).
- the agent is typically coated onto carrier particles using a variety of techniques known in the art.
- Carrier particles are selected from materials which have a suitable density in the range of particle sizes typically used for (e.g. intracellular) delivery from a gene gun device. The optimum carrier particle size will, of course, depend on the desired target (e.g. diameter of the target cells).
- tungsten, gold, platinum and iridium carrier particles can be used.
- Tungsten and gold particles are preferred.
- Tungsten particles are readily available in average sizes of 0.5 to 2.0 ⁇ m in diameter. Such particles have optimal density for use in particle acceleration delivery methods, and allow highly efficient coating with DNA.
- Gold particles or microcrystalline gold e.g., gold powder A1570, available from Engelhard Corp., East Newark, NJ
- gold powder A1570 available from Engelhard Corp., East Newark, NJ
- provide uniformity in size available from Alpha Chemicals in particle sizes of 1-3 ⁇ m, or available from Degussa, South Plainfield, NJ in a range of particle sizes including 0.95 ⁇ m
- Microcrystalline gold provides a diverse particle size distribution, typically in the range of 0.5-5 ⁇ m.
- a number of methods are known and have been described for coating or precipitating agents onto particles (e.g. combining a predetermined amount of gold or tungsten with plasmid DNA, CaCl 2 and spermidine).
- the resulting solution is vortexed continually during the coating procedure to ensure uniformity of the reaction mixture.
- the coated particles can be transferred to suitable membranes and allowed to dry prior to use, coated onto surfaces of a sample module or cassette, or loaded into a delivery cassette for use in particular gene gun instruments.
- particles coated with the agent are delivered using particle-mediated delivery techniques.
- Suitable particle acceleration devices are known in the art. Typically such a device employs an explosive, electric or gaseous discharge to propel coated particles towards the target.
- the coated particles can themselves be releasably attached to a movable carrier sheet, or removably attached to a surface along which a gas stream passes, lifting the particles from the surface and accelerating them toward the target.
- An example of a gaseous discharge device is described in U.S. Patent No. 5,204,253.
- An explosive-type device is described in U.S. Patent No. 4,945,050.
- One example of an electric discharge-type particle acceleration apparatus is the ACCELL M instrument (Geniva, Madison, Wl), which instrument is described in U.S. Patent No. 5,120,657. Another electric discharge apparatus suitable for use herein is described in U.S. Patent No. 5,149,655.
- a single administration may include more than one gene gun dose, e.g. two to six gene gun doses.
- the dose of vaccination agent administered may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient.
- a suitable dose may however be from 10 ⁇ g to lOg, for example from 100 ⁇ g to lg of the vaccination agent or T cells. These values may represent the total amount administered in the complete treatment regimen or may represent each separate administration in the regimen.
- the polypeptides of the invention may be formulated into the vaccine as neutral or salt forms.
- Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with - inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine and procaine.
- inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic.
- Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethyl
- transfection agents may also be administered to enhance the uptake of the expression vector by cells.
- suitable transfection agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam and transfectam ).
- the vaccination agent is in the form of a viral vector the amount of virus administered is in the range of from 10 4 to 10 12 pfu, preferably from 10 7 to 10 10 pfu (for example for adeno viral vectors), more preferably about 10 8 pfu for. herpes viral vectors.
- a pox virus vector may also be used (e.g. vaccinia virus), typically at any of the above dosages.
- When injected typically 1-2 ml of virus in a pharmaceutically acceptable suitable carrier or diluent is administered.
- cells are admimstered typically 10 to 10 cells, preferably 10 to 10 cells are admimstered.
- Homologous sequences are mentioned herein. Such sequences typically have at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% homology with the relevant sequence, for example over a region of at least 15, 20, 40, 100 more contiguous amino acids (of the homologous sequence). Methods of measuring protein homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").
- the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395).
- the PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10.
- HSPs high scoring sequence pair
- Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
- the BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787.
- One measure orsimilarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
- P(N) the smallest sum probability
- a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- the homologous sequence typically differs from the relevant sequence by at least (or by no more than) 2, 5, 10, 15, 20 more mutations (which may be substitutions, deletions or insertions). These mutations may be measured across any of the regions mentioned above in relation to calculating homology.
- the substitutions are preferably "conservative". These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
- this typically differs from the epitope sequence (such as SEQ ID NO:l or 2) by at least (or no more than) 1, 2, 3, 4 or more mutations (which may be insertions, deletion or substitution (e.g. conservative substitutions)).
- Homologous sequences mentioned herein may be encoded by a polynucleotide which hybridises to a polynucleotide that encodes the relevant polypeptide, typically hybridising selectively at a level significantly above background.
- Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.003M sodium citrate at from about 50°C to about 60°C).
- medium to high stringency for example 0.03M sodium chloride and 0.003M sodium citrate at from about 50°C to about 60°C.
- suitable conditions include 0.2 x SSC at 60°C.
- suitable conditions include 2 x SSC at 60°C.
- Healthy BCG vaccinated blood donors were recruited from the Banjul Blood Bank, Royal Victoria Hospital. Blood samples were obtained only after informed consent was given and only after a BCG scar was identified as proof of vaccination. HLA class-I genotyping was kindly performed by Dr. A. Jaye (MRC Laboratories, Fajara, Gambia).
- tuberculosis H37Rv was analyzed: probable Signal peptidase-I (Rv2903c). Peptides were selected for this study when they ranked in the top-5 of best binding peptides of both algorithms and when a Proline (P) at position 2 was present as potential anchor residue. Based on the presence of an aromatic (F, Y, W) or hydrophobic (V, L, I, M) anchor residue at the C-terminus 8-, 9-, and 10-mer peptides were selected to determine HLA-binding properties.
- Lyophilized 8-mer to 10-mer peptides were purchased from Research Genetics, Inc. (Huntsville, AL, USA). Peptides were synthesized using Fmoc- chemistry and analyzed with HPLC and mass spectrometry. Upon arrival peptides were dissolved in 400 ⁇ l dimethyl-sulfoxide (DMSO) and diluted in 0.9% NaCl to a concentration of 10 mM. Peptide stocks were aliquotted, stored at -70°C and once in use kept at 4°C. Peptides known to bind to HLA-B*35 were used as positive controls, including HIV-1 SF2 Nef 72-80 (4T6R) (FPVTPRVPL) and Epstein-Barr virus
- HLA-A3 restricted-CD 8 T cell epitope was selected from Influenza A virus Nucleoprotein NP 265- 273 (ILRGSVAHK) (DiBrino et al. J. Immunol. 151, 5930-5935, 1993). Fluorescein (FL)-labeled reference peptides were synthesized as Lysine- derivatives of positive control peptides and were also obtained from Research Genetics, Inc.
- Binding assays were performed essentially as described (Schonbach et al, 1995; Takamiya et al, Int. Immunol. 6, 255-261, 1994; Van der Burg et al, Hum. Immunol. 44, 189-198, 1995). Briefly, Tap-deficient RMA-S cells expressing human ⁇ 2-microglobulin and HLA-B*3501 (generously provided by Prof. Dr. M.
- Binding peptides which reduced the maximum signal of the FL-labeled reference peptide by >75%, were subsequently tested in eight serial 2-fold dilutions to determine the concentration at which the maximum signal was inhibited by 50% (IC 50 ). The latter was used as a direct measure of peptide binding (Van der Burg et al, 1995). Alternatively, RMA-S cells were pulsed with 50 ⁇ M peptide for 16 h at 26°C followed by 3 h at 37°C. In case of stabilization assays to determine the half- life of peptide-HLA class-I complexes on the cell surface (Van der Burg, J.
- HLA class-I surface expression was measured immediately to determine the level of HLA class-I surface expression. The latter was used as an indirect measure of peptide binding, since HLA class-I surface expression rapidly disappears at 37°C in case peptides do not significantly bind (Schonbach et al, 1995; Takamiya et ⁇ /, 1994).
- Antigen-specific CD8+ T cells were expanded from PBMC as previously has been described (Lalvani et al, J. Immunol. Methods 210, 65-77, 1997). Briefly, PBMC were pulsed with 50 ⁇ M of peptide for 1 hour at room temperature. Cells were cultured in RPMI-1640 supplemented with 10% autologous plasma, antibiotics and 5 ng/ml recombinant human IL-7 (R&D Systems Europe Ltd., Abingdon, UK). On day 3 and every 3-4 days thereafter complete medium was added containing 10 U/ml rlL- 2 (generously provided by Dr. R.
- effector cells were tested at different E/T ratios on Cr-labeled target cells.
- Target cells were autologous monocyte-derived-macrophages pulsed with peptide or acutely infected with M.tuberculosis H37Ra, or autologous EBV- transformed B-LCL pulsed with peptide.
- Supematants were harvested after 4-6 hours and mixed with OptiPhase SuperMix scintillant (Wallac Scintilation Products, Fisher
- Chromium release was measured using a 1450- MicroBeta Trilux liquid scintillation counter (Wallac, Turku, Finland) and expressed as specific lysis (%) using the following formula: [(experimental release-spontaneous release) ⁇ (maximum release-spontaneous release)] x 100%.
- Activated CD8 + T cells from short-term bulk cultures were analyzed for intracellular IFN ⁇ production in response to mycobacteria-derived peptides essentially as previously has been described (Kern et al, Nat. Med. 4, 975-978, 1998). Briefly, short-term bulk cultures were harvested and 2 x 10 6 cells were incubated for 4-6 hours at 37°C/5%C0 2 with 10 6 target cells pulsed with peptide.
- Target cells were autologous EBV-transformed B-LCL or RMA-S B*3501 transfected cells. During the last 4 hour Brefeldin A (Sigma Chemical Co., Poole, UK) was added (final concentration lO ⁇ g/ml). Cells were harvested and washed once with PBS/0.3% (w/v; BSA. Becton Dickinson Immunocytometry Systems (BDIS) (San Jose, CA, USA) reagents and protocols were used to perform intracellular staining of cytokines. Briefly, cells were incubated with FACSTM Lysing Solution (BDIS) and FACSTM Permeabilizing Solution (BDIS) according to manufacturer's instructions. Subsequently, cells were stained using the following antibodies:
- CaliBRYFETM beads and FACSCompTM software were used to optimize instrument settings prior to use. Data was acquired and analyzed using CellQuestTM software. Data is displayed as two-color dot plots to determine the level of cytokine expression in activated CD8+ T cells.
- M.tuberculosis H37Rv-derived sequences of Signal peptidase-I were searched for HLA-B*35 peptide binding motifs. Peptides were selected when they ranked among the 5 best binding peptides according to the Epimatrix and BIMAS algorithms and when they contained a Proline on position 2 as anchor residue. The peptides were first tested for their ability to stabilize HLA-B*3501 molecules at a fixed and saturating concentration of 50 ⁇ m ( Figure 1). The positive control peptides HIV-1 SF 2 Nef (aa. 72-80)-4T6R and EBV TEGU (aa. 1974-1982) gave strong and reproducible inhibition of the maximum signal of the FL-labeled reference peptide. Only peptide SPase-I 201-2 Q 9 inhibited >75% and was considered for further testing.
- Peptide SPase-I 2 o ⁇ -2 0 9 was subsequently tested in eight serial 2-fold dilutions to determine the concentration at which it inhibited the signal of 1 ⁇ M FL-labeled reference peptide by 50% (IC 50 ). Titration of the peptides resulted in reproducible dose-response curves, with an IC 5 0 value of 1.6 to 2.1 ⁇ M ( Figure 2).
- the IC 5 o-value of HLA-B*3501 binding peptide HIV-1 SF2 Nef (aa. 72-80)-4T6R was between 0.6 - 1.3 ⁇ M.
- PBMC from a BCG vaccinated healthy donor were stimulated with peptide SPase-I 201 - 209 -
- Short-term bulk cultures were tested for their ability to kill peptide pulsed-target cells and M.tuberculosis-infected autologous macrophages.
- the peptide was able to induce cell-mediated cytotoxicity against peptide-pulsed macrophages as well as against M.tuberculosis-infected macrophages (Figure 4).
- Bulk cultures were also tested for IFN ⁇ and TNF ⁇ production by activated CD8 + T cells ( Figure 5).
- Peptide SPase-I 2 o ⁇ -2 09 was able to induce intracellular IFN ⁇ and TNF ⁇ production in activated (i.e.
- CD69* CD8 cells.
- the number of activated CD8+ T cells producing IFN ⁇ was 22.5% when using autologous cells pulsed with peptide SPase-I 20 ⁇ -2 0 9, whereas only 0.1% of cells were positive when tested on target cells pulsed with control peptide HIV-1 SF2 Nef7 2-8 o (4T6R) ( Figure 5).
- TNF ⁇ we observed in response to peptide SPase-I 20 1- 2 0 9 about 14.4% activated CD8 T cells with control targets only 0.3%. Comparable results were obtained when we used the autologous B-LCL as targets (not shown).
- HLA-B*07, -B*3501, -B*5l, -C*w0401 and H-2L d peptide-binding motifs see http://bimas.dert.nih.gov/molbio/hla_bind/) (Parker et al, J. Immunol. 152, 163-175, 1994).
- predictions of potential HLA-B*07 and -B*35 restricted CTL epitopes were done using the EpiMatrix software in collaboration with Dr. A.S. de Groot (TB/HIV Research Lab, Brown University, Buffalo, RI, USA) (De Groot et al, AIDS Res. Hum.
- Retroviruses _3, 529-531, 1997 Peptides were selected based on the following criteria: a) 10-mer sequences with COVER value ⁇ 50% for significant binding to HLA-B*35 according to EpiMatrix calculations, b) corresponding 9-mer sequences ranking in the top- 10 of best binding peptides according to BIMAS algorithm, and c) a Proline (?) as anchor residue at position-2 according to the HLA-B7 supermotif (Sidney et al, Immunol. Today 17, 261-266, 1996a; Sidney et al. J. Immunol. 157, 3480-3490, 1996b).
- Lyophilised 8 to 10-mer peptides were purchased from Research Genetics, Inc. (Huntsville, AL, USA). Peptides were synthesised using Fmoc-chemistry and analysed with HPLC and mass spectrometry. Upon arrival peptides were dissolved in 40 ⁇ l dimethyl-sulfoxide (DMSO) and diluted in 0.9% NaCl to a concentration of 10 mM. Peptide stocks were aliquotted, stored at -70°C and once in use kept at 4°C. Peptides known to bind to HLA-B*35 were used as positive controls, including HIV- 1 S F 2 Nef (aa.
- HLA-A3 restricted-CD 8 T cell epitope was selected from Influenza A virus Nucleoprotein (aa. 265-273) ILRGSVAHK (DiBrino et al, J. Immunol. L51, 5930- 5935, 1993). Fluorescein (FL)-labeled reference peptides were synthesised as Cys- and Lys-derivatives of positive control peptides and were also obtained from Research Genetics, Inc.
- Binding peptides which reduced the maximum signal of the FL- labeled reference peptide by >75%, were subsequently tested in eight serial 2-fold dilutions to determine the concentration at which the maximum signal was inhibited by 50% (IC 50 ). The latter was used as an indirect measure of peptide binding (Van der Burg et al, 1995).
- RMA-S cells were pulsed with 50 ⁇ M peptide for 16 h at 26°C followed by 3 h at 37°C. In case of stabilization assays to determine the half-life of peptide-HLA class-I complexes on the cell surface (Van der Burg, J.
- Peptides were selected from M.tuberculosis-de ⁇ ved antigens, based on a significant binding score to HLA-B*3501 using the EpiMatrix software (COVER value ⁇ 50%), ranking among the best 10 binders according to the BIMAS algorithm and with a Proline at position 2 as anchor residue. The latter was being done with the hope to select for peptides and also able to bind to other members of the HLA-B7 superfamily (Sidney et al, 1996a; Sidney et al, 1996 b).
- the peptides were first tested for their ability to bind and stabilise HL A- B*3501 molecules at a fixed and saturating concentration of 50 ⁇ M. IC 50 values were determined. The stability of the peptides complexed to HLA-B*3501 was assessed by detecting the level of HLA class-I surface expression over a 2 to 9 h period, and the half-life (TV2) was determined. Peptides were also tested for their ability to bind and stabilise HLA-B* 3501 molecules. The results are shown in the Table below:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001240897A AU2001240897A1 (en) | 2000-03-20 | 2001-03-20 | Epitopes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0006692.8 | 2000-03-20 | ||
GBGB0006692.8A GB0006692D0 (en) | 2000-03-20 | 2000-03-20 | Epitopes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001070764A2 true WO2001070764A2 (fr) | 2001-09-27 |
WO2001070764A3 WO2001070764A3 (fr) | 2001-12-20 |
Family
ID=9888005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/001205 WO2001070764A2 (fr) | 2000-03-20 | 2001-03-20 | Epitopes |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001240897A1 (fr) |
GB (1) | GB0006692D0 (fr) |
WO (1) | WO2001070764A2 (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624456D0 (en) * | 1996-11-25 | 1997-01-15 | Isis Innovation | Assay method |
KR100692227B1 (ko) * | 1998-04-07 | 2007-03-09 | 코릭사 코포레이션 | 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 |
-
2000
- 2000-03-20 GB GBGB0006692.8A patent/GB0006692D0/en not_active Ceased
-
2001
- 2001-03-20 AU AU2001240897A patent/AU2001240897A1/en not_active Abandoned
- 2001-03-20 WO PCT/GB2001/001205 patent/WO2001070764A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001070764A3 (fr) | 2001-12-20 |
AU2001240897A1 (en) | 2001-10-03 |
GB0006692D0 (en) | 2000-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2721574C2 (ru) | Вакцинная композиция против злокачественной опухоли | |
AU778701B2 (en) | MUC-1 derived peptides | |
US20220111030A1 (en) | Antigen specific multi epitope-based anti-infective vaccines | |
AU778449B2 (en) | MAGE-A1 peptides presented by HLA class II molecules | |
CN100415771C (zh) | 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途 | |
CA2394741A1 (fr) | Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques | |
US8043623B2 (en) | Immunogenic peptides for the treatment of prostate and breast cancer | |
US7115361B2 (en) | Detection of CD8+ T cell responses to M. tuberculosis | |
Zhu et al. | Specificity of CD8+ T cells from subunit-vaccinated and infected H-2b mice recognizing the 38 kDa antigen of Mycobacterium tuberculosis. | |
JP4945444B2 (ja) | Hla−a3スーパータイプアレル分子陽性前立腺癌患者に対する癌ワクチン候補となる前立腺関連蛋白由来ペプチド | |
EP0964697B1 (fr) | Applications therapeutiques d'antigenes ou d'epitopes associes a un traitement peptidique cellulaire altere, exprimes par exemple sur des cellules rma-s transfectees avec un gene b7-1 | |
WO2001070991A1 (fr) | Vaccin contre l'infection par le mycobacterium tuberculosis basé sur des épitopes du complexe ag85 | |
WO2005092918A2 (fr) | Polypeptide de ciblage | |
WO2001070764A2 (fr) | Epitopes | |
US20040037837A1 (en) | Mycobacterium ag85 complex-specific t cell peptides and use in diagnostic and therapeutic applications thereof | |
Dow et al. | Immunization with f-Met peptides induces immune reactivity against Mycobacterium tuberculosis | |
Munk et al. | Epitopes of the mycobacterial heat shock protein 65 for human T cells comprise different structures | |
RU2731073C1 (ru) | Вакцина против герпеса | |
EP1211260A1 (fr) | Peptides de Ag85 de mycobacterium et leurs utilisation | |
WO2024219974A1 (fr) | Néo-antigènes teipp dérivés du timp3 et leurs utilisations | |
JP4961706B2 (ja) | Hlaクラスii拘束性新規癌抗原ペプチド | |
WO2000043511A1 (fr) | Polypeptide | |
Are | Identification of Major Epitopes of | |
WO2011112599A2 (fr) | Peptides pote immunogènes et leurs procédés d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |